Evaluation of the efficacy and safety of a Russian selective immune suppressor in treating patients with psoriasis
A. A. Kubylinskiy, N. G. Korotkiy, A. A. Tikhomirov, V. Yu. Udzhukhu, N. M. Sharova · 2014 · Clinical Dermatology and Venereology. 2014;12(5):68–74
Reported findings and study design
140-patient clinical comparison; the quoted PASI response appears within the moderate-psoriasis discussion.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| PASI reduction greater than 75% by day 25 | 90% with Thymodepressin versus 41% with conventional care |
The subgroup denominator is not verified; these percentages must not be described as responses among all 140 participants. Blinding, allocation and concurrent treatment limit attribution.
Source for the extracted data ↗ · Checked 2026-11-05
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- The PASI percentages appear in the moderate-psoriasis discussion; do not assign them to all 140 patients.
- Blinding and allocation concealment are not established. Concurrent care and treatment selection limit causal attribution.
- The comparator reflects conventional care at publication, not contemporary targeted biologics.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Publisher Russian full text checked. Issue year is 2014; the later website posting date is not a new study date.
Recorded source-check date: 2026-11-05. This date does not imply a completed systematic review.
Citation and original source
Original source: A. A. Kubylinskiy, N. G. Korotkiy, A. A. Tikhomirov, V. Yu. Udzhukhu, N. M. Sharova. Evaluation of the efficacy and safety of a Russian selective immune suppressor in treating patients with psoriasis Clinical Dermatology and Venereology. 2014;12(5):68–74 2014.
Molekul research summary: https://molekul.io/research/auto-thymodepressin-psoriasis-2014. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry